Compare AGEN & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | SMTI |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | United States | United States |
| Employees | N/A | 108 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.8M | 322.2M |
| IPO Year | 1999 | 2008 |
| Metric | AGEN | SMTI |
|---|---|---|
| Price | $7.71 | $35.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | $26.33 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.1M | 154.6K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $42,877,086.00 | $15,586,976.00 |
| Revenue This Year | $9.64 | $13.07 |
| Revenue Next Year | N/A | $14.23 |
| P/E Ratio | $7.85 | ★ N/A |
| Revenue Growth | ★ 89.95 | 32.47 |
| 52 Week Low | $2.71 | $16.05 |
| 52 Week High | $10.19 | $35.34 |
| Indicator | AGEN | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 63.56 |
| Support Level | $6.51 | $34.63 |
| Resistance Level | $8.64 | $35.34 |
| Average True Range (ATR) | 0.63 | 0.19 |
| MACD | -0.18 | -0.11 |
| Stochastic Oscillator | 14.75 | 59.86 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.